The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.
Precision Medicine Online
图书期刊出版业
New York，New York 14,645 位关注者
Precision Medicine Online covers the adoption of precision medicine in all disease areas.
关于我们
Precision Medicine Online is published by GenomeWeb, an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and diagnostics. GenomeWeb is a business unit of Crain Communications. Precision Medicine Online launched in 2023 as an expansion of Precision Oncology News, which was created in 2019 to cover the application of genomic sequencing and other biomarker-driven approaches to guide cancer treatment. While oncology has led the way in adopting molecularly informed approaches to diagnostics, monitoring, and treatment, GenomeWeb is committed to informing our readers about the adoption of precision medicine in all disease areas, and this relaunch reflects this broader scope of coverage. Our dedicated online newsroom tracks the industry players and healthcare systems driving the adoption of precision medicine in oncology, rare disease, cardiovascular disease, autoimmune disease, pharmacogenomics, and more; regulatory, policy, legal, and ethical issues affecting the field; and the challenges of implementing precision medicine as the standard of care.
- 网站
-
https://www.precisionmedicineonline.com/
Precision Medicine Online的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 11-50 人
- 总部
- New York，New York
- 创立
- 2019
动态
-
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
Illumina Incorporates Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
precisionmedicineonline.com
-
The firm will test the activity of NEU-411 in patients with Parkinson's caused by LRRK2 mutations or whose disease is influenced by LRRK2 overactivity.
Neuron23 to Launch Phase II Trial in LRRK2-Driven Parkinson's in Early 2025
precisionmedicineonline.com
-
The trial will include patients with CXCR4-positive acute myeloid leukemia and acute lymphoblastic leukemia.
Pentixapharm Begins Phase I/II Trial of Radiopharmaceutical Agent in Leukemia
precisionmedicineonline.com
-
The approval is based on the objective response rate in a Phase IIb trial of previously treated, unresectable or metastatic biliary tract cancer patients.
Jazz Pharmaceuticals Nabs FDA Accelerated Approval for Ziihera in HER2-Positive Biliary Tract Cancer
precisionmedicineonline.com
-
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
Illumina Incorporates Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
precisionmedicineonline.com
-
The PRECEDE Consortium will help with the clinical evaluation of Breakthrough's blood-based pancreatic cancer early detection test.
Breakthrough Genomics Partners With PRECEDE Pancreatic Cancer Consortium
-
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 mutation but she wasn't told.
Genetic Testing Challenges in Precision Medicine: Li-Fraumeni Diagnosis Missed in Young Patient
precisionmedicineonline.com
-
As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role for biomarkers to guide their use.
Is There a Role for Precision Medicine With GLP-1 Drugs?
precisionmedicineonline.com
-
In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue giving them an experimental drug.
Mayo Clinic Studying Use of Neurofilament as Biomarker to Guide Treatment of ALS Patients
precisionmedicineonline.com